Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic Agents

Joyce A. OShaughnessy, MD
Published: Thursday, Jul 17, 2014

Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.

It is difficult to understand different types of triple-negative breast cancer (TNBC) today, O’Shaughnessy says, as there are no laboratory tests in this space. There are data coming out that show certain chemotherapy agents may be more effective for TNBC than they are for ER-positive disease.

O’Shaughnessy says that there are some subtype-specific differences with cytotoxic agents but we are still in the early days of research.

Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.

It is difficult to understand different types of triple-negative breast cancer (TNBC) today, O’Shaughnessy says, as there are no laboratory tests in this space. There are data coming out that show certain chemotherapy agents may be more effective for TNBC than they are for ER-positive disease.

O’Shaughnessy says that there are some subtype-specific differences with cytotoxic agents but we are still in the early days of research.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x